According to Gilead Sciences's latest financial reports the company has a price-to-book ratio of 4.01.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2023-12-31 | 4.44 | -12.6% |
2022-12-31 | 5.08 | 17.45% |
2021-12-31 | 4.32 | 7.85% |
2020-12-31 | 4.01 | 10.35% |
2019-12-31 | 3.63 | -2.47% |
2018-12-31 | 3.72 | -18.42% |
2017-12-31 | 4.56 | -6.31% |
2016-12-31 | 4.87 | -35.28% |
2015-12-31 | 7.53 | -15.71% |
2014-12-31 | 8.93 | -8.96% |
2013-12-31 | 9.81 | 67.83% |
2012-12-31 | 5.85 | 30.58% |
2011-12-31 | 4.48 | -5.7% |
2010-12-31 | 4.75 | -20.67% |
2009-12-31 | 5.98 | -42.6% |
2008-12-31 | 10.4 | -12.16% |
2007-12-31 | 11.9 | -25.91% |
2006-12-31 | 16.0 | 100.72% |
2005-12-31 | 7.98 | -4.91% |
2004-12-31 | 8.39 | -32.26% |
2003-12-31 | 12.4 | 5.38% |
2002-12-31 | 11.8 |
Company | P/B ratio | differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | 5.54 | 38.18% | ๐บ๐ธ USA |
Pfizer PFE | 1.76 | -56.13% | ๐บ๐ธ USA |
AbbVie ABBV | 31.0 | 673.13% | ๐บ๐ธ USA |
Eli Lilly LLY | 68.1 | 1,597.35% | ๐บ๐ธ USA |
Amgen AMGN | 24.5 | 509.53% | ๐บ๐ธ USA |
Biogen BIIB | 2.12 | -47.03% | ๐บ๐ธ USA |
Illumina ILMN | 3.84 | -4.38% | ๐บ๐ธ USA |
Vertex Pharmaceuticals VRTX | 6.14 | 53.11% | ๐บ๐ธ USA |
Merck MRK | 8.88 | 121.36% | ๐บ๐ธ USA |